Novo launches NovoCare Pharmacy with Wegovy at $499 a month

Novo Nordisk on March 5, 2025 launched NovoCare Pharmacy, a direct-to-patient service that ships all dose strengths of FDA-approved Wegovy (semaglutide) to a patient's home for $499 for a 28-day supply ^[3]. The offer applies to cash-paying patients — people who are uninsured, or who have commercial insurance that does not cover obesity medicines ^[3].

The $499 price covers the 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg single-dose pens ^[3]. For comparison, Novo Nordisk's own website listed the 28-day list price for Wegovy at $1,349 ^[4]. Before NovoCare Pharmacy opened, patients without coverage could use a savings card that brought the monthly cost to $650 ^[4].

Prescriptions are written by a licensed clinician and sent to NovoCare Pharmacy, with the medicine dispensed and delivered by CenterWell Pharmacy ^[3][4]. The program also offers benefit verification, refill reminders and access to a NovoCare case manager ^[3]. Novo said at launch that it would later update the savings offer so cash-paying patients using regular retail pharmacies could get the same lower price ^[3]; by early May, Becker's reported that eligible self-paying patients could get the $499 price at a local pharmacy ^[2].

There are real limits. According to the program's terms, NovoCare Pharmacy is cash-pay only: people enrolled in any federal or state health program, including Medicare or Medicaid, are not eligible, and commercial insurance is not accepted ^[4]. Novo Nordisk framed the launch around insurance gaps, saying more than 55 million people in the U.S. have coverage specifically for weight-management medicines and that 90% of Wegovy patients with coverage pay $0 to $25 a month ^[3].

The timing followed the FDA's determination that the semaglutide shortage was resolved, with all Wegovy dose strengths meeting or exceeding current and projected U.S. demand ^[3]. Novo also pitched the pharmacy as a way to avoid "fake or illegally compounded semaglutide" ^[4].

Why it matters for patients

For someone paying out of pocket, this cut the monthly cash price roughly in half compared with the prior $650 savings-card price, and to about a third of the $1,349 list price ^[4]. Over a year, $499 a month still comes to nearly $6,000 before any doctor visits or lab work.

Clinicians quoted by Healio were cautiously positive but skeptical about how many people could actually afford it. "It's definitely a lot of money, so I don't know what the uptake will be," said Diana Isaacs, PharmD, an endocrine clinical pharmacy specialist at Cleveland Clinic. "I'm sure [uptake] will be better than when it was $650. But it's still pretty expensive" ^[4]. Katherine H. Saunders, MD, of FlyteHealth and Weill Cornell Medicine, said the price remains "out of reach" for most patients without coverage, and that cost is only one barrier alongside "insurance coverage, number of qualified clinicians and weight bias, stigma and discrimination" ^[4].

The launch also landed as compounded semaglutide was being wound down. Healio reported that state-licensed compounding pharmacies operating under section 503A could no longer distribute compounded semaglutide after April 22, 2025, and 503B outsourcing facilities had to stop manufacturing it after May 22, 2025 ^[4]. Isaacs predicted the transition would be slow: "I think it's going to take a while before the compounding pharmacies fully dissipate" ^[4].

NovoCare Pharmacy also differs from Eli Lilly's LillyDirect, which launched in January 2024, covers multiple medicines, partners with telehealth providers and accepts most insurance for some products; at launch NovoCare was Wegovy-only and had no telehealth partners ^[4].

What happens next

• Late February 2025: Eli Lilly began selling higher doses of Zepbound (tirzepatide) at $499 for a first fill, with 7.5 mg and 10 mg single-dose vials then priced at $599 and $699 through its direct-to-consumer platform ^[2].
• April 22 and May 22, 2025: Deadlines for 503A and 503B compounders, respectively, to stop distributing or making compounded semaglutide ^[4].
• Late April 2025: Novo expanded its arrangement with Humana's CenterWell Pharmacy, and telehealth providers Hims & Hers, LifeMD and Ro began working with NovoCare to prescribe Wegovy to self-pay patients ^[2].
• July 1, 2025: CVS Caremark made Wegovy the preferred GLP-1 for obesity on its largest commercial template formularies ^[2].

How many patients signed up at $499 is not reported in these sources.